EICHOR
● Recruiting
Comprehensive Assessment of Cancer Theranostic Response
Condition: Prostate Cancer · Sponsor: AIQ Solutions
About this study
The intent of this study is to evaluate actionable outputs from TRAQinform Theranostics in a prospective, multi-center, non-interventional clinical study. The primary objective is to investigate intent-to-change treatment decisions after the addition of TRAQinform Theranostics. The exploratory objective is to investigate if treatment efficacy and treatment-related toxicity could be detected by TRAQinform Theranostics following PSMA PET/CT at week 12.
This description comes directly from the study's public registry record.
Talk to the study team
Dona Alberti, RN, MSN · 608-268-9684 · dona.alberti@aiq-solutions.com
Tim Perk, PhD · 608-268-9684 · tim.perk@aiq-solutionsc.com
Always discuss trial participation with your own doctor first.
Locations (2)
| Weill Medical College of Cornell | New York, New York, United States | Recruiting |
| M.D. Anderson Cancer Center | Houston, Texas, United States | Recruiting |
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06815354